<?xml version="1.0" encoding="UTF-8"?>
<p id="Par47">ACE2 is particularly expressed on the type II alveolar epithelial cells (Guan et al. 
 <xref ref-type="bibr" rid="CR32">2020a</xref>; Guan et al. 
 <xref ref-type="bibr" rid="CR33">2020b</xref>; Wang and Xu 
 <xref ref-type="bibr" rid="CR96">2020</xref>; Yang et al. 
 <xref ref-type="bibr" rid="CR111">2020a</xref>; Yang et al. 
 <xref ref-type="bibr" rid="CR112">2020b</xref>; Yang et al. 
 <xref ref-type="bibr" rid="CR113">2020c</xref>; Zhao et al. 
 <xref ref-type="bibr" rid="CR117">2020</xref>) although also the gastrointestinal tract, kidneys, heart, brain stem, vasculature, liver, and nasal and oral mucosa express these receptors, contributing to extra-pulmonary manifestations (Zhao et al. 
 <xref ref-type="bibr" rid="CR117">2020</xref>). However, the different distribution of ACE2 in organs and tissue is significantly correlated to the clinical symptoms of SARS-CoV-2 infection (Nejadi Babadaei et al. 
 <xref ref-type="bibr" rid="CR66">2020</xref>) (Fig.Â 
 <xref rid="Fig4" ref-type="fig">4</xref>).
</p>
